Xigen is a pharmaceutical company spin-off from the University Hospital founded in 2002 in Lausanne. The company is based on comprehensive research activities in the field of intracellular peptide research and JNK inhibition. Xigen is focusing on the development of intracellular peptide therapeutics for the acute and short-term treatment of unmet medical needs in major debilitating diseases: stroke, myocardial infarction and cancer. Xigen was sold to Tilocor in 2008.